Treatment of Age-Related Cognitive Dysfunction: Pharmacological and Clinical Evaluation

Under the Patronage of the Commission of the European Communities

Volume Editors
G. Racagni, Milan
J. Mendlewicz, Brussels

39 figures and 10 tables, 1992
Fuxe, K. (Stockholm); Agnati, L.F. (Modena); Hedlund, P.; Ögren, S.O.; Bortolotti, F. (Stockholm); Carani, C.; Biagini, G. (Modena): Failure of Integrative Mechanisms in the Aging Brain .......................................................... 1
Knipper, M. (Stuttgart); Yamamura, H.I. (Tucson, Ariz.): Cholinergic Mechanism and Trophic Factors ................................................................. 19
Müller, W.E. (Mannheim): Age-Related Quantitative and Qualitative Receptor Changes and Pharmacological Reactivity ........................................ 35
Brandao, F.; Cadete-Leite, A.; Paula-Barbosa, M.M. (Porto): Morphological Brain Changes Induced by Alcohol and Aging. Effects of Piracetam during Withdrawal following Long-Term Alcohol Consumption ............................ 63
Rafféle, K.C.; Haxby, J.V.; Schapiro, M.B. (Bethesda, Md.): Age-Associated Memory Impairment ................................................................. 69
Hardy, J. (London): Alzheimer’s Disease Is Caused by Mismetabolism of the Beta-Amyloid Precursor Protein ....................................................... 80
Amaducci, L.; Lippi, A.; Bracco, L.; Falcini, M. (Florence): Definition and Classification of Age-Related Cognitive Dysfunction ............................ 86
Crook, T.H. (Bethesda, Md.): Assessment of Clinical Efficacy of Cognitive Enhancers ..................................................................................... 94
Leber, P. (Rockville, Md.): Developing Pharmacological Treatment for Age-Associated Cognitive Impairments: A Regulatory Perspective ................. 108
Sauer, F. (Brussels): Impact of European Regulations on Drug Development .... 116
Gottfries, C.G. (Mölndal): Reappraisal of Current Therapy in the Treatment of Age-Related Cognitive Disorders ......................................................... 121
Contents

Giurgea, C.E. (Braine-l'Alleud): The Next Decade in Drug Treatment of Cognitive Disorders .................................................. 137
Amaducci, L. (Florence); Crook, T.H. (Bethesda, Md.); Giurgea, C.E. (Braine-l'Alleud); Langer, S.Z. (Paris); Leber, P. (Rockville, Md.); Mendlewicz, J. (Brussels); Williams, P. (Greenford): Panel Discussion: 'Regulatory Issues in the Development of Drugs for the Treatment of Cognitive Dysfunction' .......................... 147

Subject Index ................................................................................................................. 150